Zacks Investment Research cut shares of CTI BioPharma Corp (NASDAQ:CTIC) from a buy rating to a hold rating in a research note published on Wednesday, Market Beat Ratings reports. According to Zacks, “CTI BioPharma Corp. is a biopharmaceutical …
Intercooler · 2 hours ago
BioPharma Corp
In-depth coverage >
Shares of CTI BioPharma Corp (NASDAQ:CTIC) opened at 1.23 on Tuesday. CTI BioPharma Corp has a 12-month low of $1.07 and a 12-month high of $2.94. The stock has a 50 day moving average price of $1.39 and a …
Watch List News · 12 hours ago
CTI BioPharma Corp
of $1.47B and TOUR stock 52-week range is $10.33 – $20.85 per share CTI BioPharma Corp. (Nasdaq:CTIC) said before the opening bell on Monday that a combination of its pacritinib with an epidermal growth factor receptor (EGFR) Inhibitor may improve ...
Galaxy Stocks · 11/23/2015
CTI BioPharma
More from Bing News
... and three have assigned a buy rating to the stock. CTI BioPharma Corp currently has an average rating of “Buy” and a consensus price target of $3.59. Shares of CTI BioPharma Corp (NASDAQ:CTIC) opened at 1.20 on Monday. The company has a 50 … · 1 day ago
CTI BioPharma Corp
CTI BioPharma Corp CTIC, +0.91% Everi Holdings Inc EVRI, +12.68% Boingo Wireless Inc WIFI, +8.01% and KEYW Holding Corp KEYW, -1.67% Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top …
Market Watch · 11/19/2015
CTI BioPharma
In-depth coverage >
SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday …
Financial Content · 11/24/2015
CTI BioPharma
Bianco, President and CEO at CTI BioPharma (NASDAQ:CTIC) sold 10,000 shares at $1.23 ... Macrocure (NASDAQ:MCUR) shares were among the worst performers on Monday. The stock closed 16.80% lower. uniQure ended the day 16.53% lower.
Seeking Alpha · 3 hours ago
NEW YORK (TheStreet) -- Cell Therapeutics (CTIC - Get Report) shares are climbing, up 16% to $2.94 on Thursday, after having coverage initiated with a "buy" rating by analysts at Ladenburg (LTS - Get Report). The firm set a price target of $6 on the shares ...
The Street · 5/22/2014
The stock rose as much as 10% too ... due to confirmation of a US$250mln 10-year contract from the US Postal Service. CTI BioPharma Corp (NASDAQ:CTIC) jumped 9.1% to US$1.20 after the biopharmaceutical …
Proactive Investors UK · 11/23/2015
CTI BioPharma Corp (NASDAQ:CTIC), a small-cap pharmaceutical company, announced disappointing results for its investigational lead drug candidate, pacritinib, which is being developed as a treatment for patients suffering from primary or secondary ... · 3/13/2015